GART

Gene

phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase

HGNCHGNC:4163 EnsemblENSG00000159131 NCBI Gene2618

Locus: gene with protein productLocation: 21q22.11

Encodes

via encodes

The protein product this gene encodes, reached through the canonical GENE→PROTEIN (encodes) relation. Its biology, drugs, indications, trials and therapeutic evidence live on the protein's own page.

Trifunctional purine biosynthetic protein adenosine-3P22102

Protein · therapeutic target

Clinically validated target · 5 approved medicines against this target

Explore protein biology & therapeutics

Also known as

Symbols and names change; identity (the HGNC ID) does not. Previous and alternative forms are kept distinct.

Also known asPRGS · PGFT · GARS-AIRS-GART

View full nomenclature history (7)

Previous symbolsPRGS, PGFT

Alias symbolsGARS-AIRS-GART

Alias namesGAR transformylase, glycinamide ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide ribonucleotide transformylase, Glycinamide ribonucleotide formyltransferase, Trifunctional purine biosynthetic protein adenosine-3

Associated diseases

via associated_with

Diseases linked to this gene through the canonical GENE→DISEASE (associated_with) relation, drawn from Open Targets' top-ranked associations by overall score — not the full association set. Disease-level detail lives on each disease's own page.

Carcinoma, Non-Small-Cell Lung

Malignant pleural mesothelioma

Adenocarcinoma

Neoplasms

Adenocarcinoma of Lung

Lung Neoplasms

Uterine Cervical Neoplasms

Drawn from Open Targets’ top 10 associations by overall score for this gene — the subset resolved to a canonical disease. Lower-ranked associations, and diseases not yet canonicalised, are not shown.

Gene family

HGNC gene-group membership.

PurinosomeATP-grasp fold containing

Provenance

HGNCCanonical human gene identity from HGNC (release 2026-07-07), updated 2023-01-20.

Open TargetsGene–disease associations from the Open Targets Platform.